PAX Financial Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$309K Sell
2,218
-554
-20% -$77.6K 0.05% 160
2025
Q4
$340K Sell
2,772
-94
-3% -$11.4K 0.06% 167
2025
Q3
$318K Sell
2,866
-276
-9% -$31.4K 0.06% 178
2025
Q2
$348K Sell
3,142
-812
-21% -$86.4K 0.07% 176
2025
Q1
$443K Sell
3,954
-1,189
-23% -$123K 0.08% 179
2024
Q4
$475K Sell
5,143
-2,957
-37% -$266K 0.09% 171
2024
Q3
$679K Sell
8,100
-392
-5% -$29.9K 0.12% 145
2024
Q2
$583K Buy
8,492
+861
+11% +$57.5K 0.11% 154
2024
Q1
$559K Sell
7,631
-176
-2% -$13.5K 0.11% 173
2023
Q4
$576K Sell
7,807
-584
-7% -$45.4K 0.12% 165
2023
Q3
$629K Sell
8,391
-2
-0% -$154 0.14% 128
2023
Q2
$647K Sell
8,393
-716
-8% -$57.1K 0.15% 127
2023
Q1
$756K Buy
9,109
+28
+0.3% +$2.32K 0.18% 88
2022
Q4
$780K Sell
9,081
-3,325
-27% -$263K 0.2% 82
2022
Q3
$765K Buy
12,406
+85
+0.7% +$5.36K 0.2% 84
2022
Q2
$762K Buy
12,321
+579
+5% +$35.8K 0.19% 79
2022
Q1
$698K Buy
11,742
+2,039
+21% +$130K 0.16% 115
2021
Q4
$705K Buy
9,703
+13
+0.1% +$895 0.16% 119
2021
Q3
$677K Buy
9,690
+120
+1% +$8.43K 0.17% 112
2021
Q2
$659K Buy
9,570
+491
+5% +$32.8K 0.17% 102
2021
Q1
$587K Buy
9,079
+541
+6% +$34.9K 0.17% 98
2020
Q4
$497K Buy
8,538
+1,526
+22% +$92.1K 0.16% 94
2020
Q3
$443K Buy
7,012
+1,672
+31% +$116K 0.16% 94
2020
Q2
$411K Buy
5,340
+333
+7% +$25.5K 0.16% 87
2020
Q1
$399K Buy
5,007
+351
+8% +$24.3K 0.17% 74
2019
Q4
$312K Buy
+4,656
New +$303K 0.13% 88

Other funds holding GILD

PAX Financial Group's GILD Position: Q1 2026 in Review

PAX Financial Group reduced its Gilead Sciences (GILD) stake by 20% in Q1 2026, selling an estimated $77.6K and leaving 2,218 shares worth $309K. The position accounts for 0.05% of the portfolio, ranked #160.

PAX Financial Group first reported a position in GILD in Q4 2019 and has held it in 26 quarters since. The position peaked at $780K in Q4 2022. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • PAX Financial Group held 2,218 shares of Gilead Sciences worth $309K as of Q1 2026.
  • PAX Financial Group sold 554 Gilead Sciences shares in Q1 2026, an estimated $77.6K.
  • Gilead Sciences made up 0.05% of PAX Financial Group's portfolio in Q1 2026, its #160 holding.
  • PAX Financial Group first reported a position in Gilead Sciences in Q4 2019 and has held it in 26 quarters since.
  • PAX Financial Group's Gilead Sciences position peaked at $780K in Q4 2022.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on PAX Financial Group's 13F filing for Q1 2026, filed 27 Apr 2026.